share_log

Adverum Biotechnologies Announces First Subject Dosed With Ixo-vec In Phase 2 LUNA Trial For Treatment Of Wet Age-Related Macular Degeneration

Adverum Biotechnologies Announces First Subject Dosed With Ixo-vec In Phase 2 LUNA Trial For Treatment Of Wet Age-Related Macular Degeneration

Adverum生物技术公司宣布,在露娜治疗湿性老年性黄斑变性的第二阶段试验中,第一个受试者服用了IxO-VEC
Benzinga Real-time News ·  2022/09/14 08:08

Adverum Biotechnologies Announces First Subject Dosed With Ixo-vec In Phase 2 LUNA Trial For Treatment Of Wet Age-Related Macular Degeneration

Adverum生物技术公司宣布,在露娜治疗湿性老年性黄斑变性的第二阶段试验中,第一个受试者服用了IxO-VEC

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发